Quarterly ResultMay 5, 2026, 04:13 PM
Jazz Pharma Q1 Revenue $1.1B (+19% YoY); EPS $4.43
AI Summary
Jazz Pharmaceuticals plc announced strong first-quarter 2026 financial results, with total revenues reaching $1.1 billion, marking a 19% year-over-year increase. The company reported GAAP diluted EPS of $4.43 and non-GAAP adjusted diluted EPS of $6.34, alongside generating $408 million in cash from operations. Key products like Xywav, Epidiolex, and Zepzelca demonstrated significant sales growth. Additionally, the FDA granted Priority Review for zanidatamab's sBLA in 1L HER2+ GEA, with a PDUFA date set for August 25, 2026, and Jazz Pharmaceuticals reaffirmed its full-year 2026 financial guidance.
Key Highlights
- Total revenues in Q1 2026 grew to $1.1 billion, a 19% increase year-over-year.
- GAAP diluted EPS was $4.43, and non-GAAP adjusted diluted EPS was $6.34.
- Generated $408 million in cash from operations during the quarter.
- Xywav net product sales increased 18% YoY to $408 million, with 425 net patient adds.
- Epidiolex/Epidyolex net product sales increased 15% YoY to $250 million.
- Zepzelca net product sales increased 60% YoY to $101 million.
- FDA granted Priority Review for zanidatamab sBLA in 1L HER2+ GEA, with a PDUFA date of August 25, 2026.
- Company reaffirmed full-year 2026 revenue guidance of $4.25 billion to $4.50 billion.